CCL5 and neoplasm: The receptor CCR1 on tumor cells from P3 (Plasma-1) exhibited a strong interaction with the ligand CCL5 on T cells, resulting in robust interactions between Plasma-1 and both CD8+Teff and Pr-Teff, which were not observed in other patients (Figure 6D; Supplementary Figure 3C).